Acer Therapeutics Receives Complete Response Letter from U.S. FDA for use of Edsivo (celiprolol) in vEDS Patients

NEWTON, MA– June 25, 2019– Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and life-threatening diseases with significant unmet...
Source: Drugs.com - New Drug Applications - Category: Drugs & Pharmacology Source Type: news